Graf Acquisition IV Stock Price, News & Analysis
gforu
Company Description
Graf Acquisition Corp. IV (GFORU) is a blank-check company focused on effecting mergers, acquisitions, and business combinations. Recently, Graf announced a business combination with NKGen Biotech, Inc., a clinical-stage biotechnology company specializing in autologous, allogeneic, and CAR-NK natural killer cell therapies. The company is actively seeking additional financing to meet the minimum cash condition required for the merger. Stockholders are encouraged to vote at the upcoming virtual Special Meeting to finalize the Business Combination.
Stock Performance
$—
0.00%
0.00
Last updated:
- %
Performance 1 year
$0.0
Market Cap
0.0
Shares outstanding
Latest News
SEC Filings
No SEC filings available for Graf Acquisition IV.
Financial Highlights
—
Revenue (TTM)
—
Net Income (TTM)
—
Diluted EPS (TTM)
—
Operating Cash Flow
—
Net Profit Margin
—
Oper. Profit Margin
Upcoming Events
Frequently Asked Questions
What is Graf Acquisition Corp. IV focused on?
Graf Acquisition Corp. IV is a blank-check company concentrating on mergers, acquisitions, and business combinations.
Who is NKGen Biotech, Inc.?
NKGen Biotech, Inc. is a clinical-stage biotechnology company specializing in innovative autologous, allogeneic, and CAR-NK natural killer cell therapies.
Why did Graf announce a business combination with NKGen?
Graf announced the business combination with NKGen to merge their operations and expertise in the biotechnology industry.
What is the goal of Graf seeking additional financing?
Graf is actively seeking additional financing to meet the minimum cash condition required for the merger with NKGen.
How can stockholders participate in the upcoming Special Meeting?
Stockholders can vote at the virtual Special Meeting to finalize the Business Combination between Graf Acquisition Corp. IV and NKGen Biotech, Inc.
Where can I find more information about NKGen Biotech, Inc.?
For more information about NKGen Biotech, Inc., visit their website at www.nkgenbiotech.com.
Who should I contact for assistance regarding the Special Meeting?
For questions or assistance regarding the Special Meeting, contact the Company's proxy solicitor, Morrow Sodali LLC, at (800) 662-5200.
What is the purpose of the upcoming Special Meeting?
The purpose of the upcoming Special Meeting is to finalize the approval of the business combination between Graf Acquisition Corp. IV and NKGen Biotech, Inc.
Why is Graf emphasizing stockholders to vote at the Special Meeting?
Graf encourages stockholders to vote at the Special Meeting to ensure the successful completion of the Business Combination with NKGen Biotech, Inc.
What are the benefits of the proposed Business Combination between Graf and NKGen?
The proposed Business Combination aims to leverage the strengths of both companies in the biotechnology sector for mutual growth and innovation.